Tumor protein translationally-controlled 1 antisense RNA 1 (TPT1-AS1)

Tumor protein translationally-controlled 1 antisense RNA 1 (TPT1-AS1) is a long non-coding RNA transcribed antisense to the TPT1 gene, located at human chromosome 13q14.13[4]. TPT1-AS1 is primarily enriched in the nucleus and sometimes the cytoplasm, where it regulates gene expression post-transcriptionally and through chromatin modification. In multiple cancers—most notably colorectal, liver, ovarian, cervical, and gastric—it is upregulated and linked to worse clinical outcomes including tumor progression, invasion, metastasis, and poor survival[1][2][4]. Mechanistically, TPT1-AS1 regulates cell cycle progression (CDK4/p21 axis), promotes epithelial-mesenchymal transition (EMT), enhances VEGFA mRNA stability to support angiogenesis, and recruits MLL1 histone methyltransferase to increase active chromatin marks (H3K4 me3) at the TPT1 gene promoter, elevating TPT1 expression[1][2][4]. Given its correlation with clinical outcomes and its central regulatory role in malignancy, TPT1-AS1 is under investigation as a biomarker and a putative therapeutic target, though no clinical drugs are yet available[1][2][4].

Other names

TPT1 antisense RNA 1lncRNA TPT1-AS1

No approved drugs directly target TPT1-AS1; potential mechanisms for future drug strategies could include: - RNA interference or antisense oligonucleotides to silence TPT1-AS1 - Inhibitors that block its interaction with chromatin modifiers or VEGFA regulation